Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis

Area of Science:

• Immunology
• Oncology
• Bone Metastasis Research

Background:

• Immunotherapy, particularly checkpoint inhibitors, shows promise for metastatic breast cancer (MBC).
• Efficacy of current immunotherapies is limited in patients with bone metastases.
• The bone microenvironment possesses immunosuppressive characteristics hindering treatment effectiveness.

Purpose of the Study:

• To elucidate the roles of the sialic acid-binding Ig-like lectin (Siglec)-15/sialic acid glyco-immune checkpoint axis in the bone metastatic niche.
• To explore therapeutic strategies targeting this glyco-immune checkpoint for breast cancer bone metastasis.

Main Methods:

• Investigated the Siglec-15/sialic acid axis within the bone metastatic niche.
• Assessed the impact of Siglec-15 on tumor-induced osteoclastogenesis and T cell responses.
• Evaluated antibody blockade of the Siglec-15/sialic acid pathway as a therapeutic strategy.

Main Results:

• Elevated Siglec-15 in the bone metastatic niche promotes tumor-induced osteoclastogenesis.
• Siglec-15 suppresses antigen-specific T cell responses in the bone microenvironment.
• Antibody blockade of the Siglec-15/sialic acid axis demonstrates potential for treating breast cancer bone metastasis.

Conclusions:

• The Siglec-15/sialic acid axis plays a critical role in immune suppression within the bone metastatic niche.
• Targeting this glyco-immune checkpoint offers a potential therapeutic strategy for breast cancer bone metastasis.
• Inhibiting this pathway may also prevent the spread of cancer from bone lesions to other organs.